| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| ROG.SW - | BUY | 370 @ CHF 410.234 | CHF 151,787 | The ETF bought 370 new shares of ROG.SW (). The shares were bought for an average price of 410.234 compared to the previous average buy price of 328.265. This is 25.0% higher than average price of previous purchases of ROG.SW. |
| NOVN.SW - | BUY | 962 @ CHF 136.745 | CHF 131,549 | The ETF bought 962 new shares of NOVN.SW (). The shares were bought for an average price of 136.745 compared to the previous average buy price of 114.81. This is 19.1% higher than average price of previous purchases of NOVN.SW. |
| LONN.SW - | BUY | 178 @ CHF 675.027 | CHF 120,155 | The ETF bought 178 new shares of LONN.SW (). The shares were bought for an average price of 675.027 compared to the previous average buy price of 642.271. This is 5.1% higher than average price of previous purchases of LONN.SW. |
| BANB.SW - | BUY | 1,100 @ CHF 73.6656 | CHF 81,032 | The ETF bought 1100 new shares of BANB.SW (). The shares were bought for an average price of 73.6656 compared to the previous average buy price of 65.7954. This is 12.0% higher than average price of previous purchases of BANB.SW. |
| - - | HOLD | 0 @ USD 0 | USD 0 | The current share valuation price of - based on adjusted close was USD 0. The average price that - shares were previous bought at was USD 0.00279608. The current market price is -100.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 007390.KQ - NatureCell Co.,Ltd. | HOLD | 0 @ KRW 15.1657 | KRW 0 | The current share valuation price of 007390.KQ based on adjusted close was KRW 15.1657. The average price that 007390.KQ shares were previous bought at was KRW 21.3643. The current market price is -29.0% lower than average price they were purchased at. The value of the holding in 007390.KQ has fallen by KRW 14,248 (USD $10) compared to the previous valuation of NatureCell Co.,Ltd. |
| 039200.KQ - Oscotec Inc. | HOLD | 0 @ KRW 31.2662 | KRW 0 | The current share valuation price of 039200.KQ based on adjusted close was KRW 31.2662. The average price that 039200.KQ shares were previous bought at was KRW 21.1692. The current market price is 47.7% higher than average price they were purchased at. The value of the holding in 039200.KQ has increased by KRW 50,115 (USD $35) compared to the previous valuation of Oscotec Inc. however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 068270.KS - CELLTRION INC | HOLD | 0 @ KRW 145.078 | KRW 0 | The current share valuation price of 068270.KS based on adjusted close was KRW 145.078. The average price that 068270.KS shares were previous bought at was KRW 122.306. The current market price is 18.6% higher than average price they were purchased at. The value of the holding in 068270.KS has increased by KRW 589,239 (USD $409) compared to the previous valuation of CELLTRION INC however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 096530.KQ - Seegene, Inc. | HOLD | 0 @ KRW 16.8969 | KRW 0 | The current share valuation price of 096530.KQ based on adjusted close was KRW 16.8969. The average price that 096530.KQ shares were previous bought at was KRW 17.5828. The current market price is -3.9% lower than average price they were purchased at. The value of the holding in 096530.KQ has fallen by KRW 2,344 (USD $2) compared to the previous valuation of Seegene, Inc. |
| 13.HK - HUTCHMED (CHINA) LTD | HOLD | 0 @ HKD 2.72065 | HKD 0 | The current share valuation price of 13.HK based on adjusted close was HKD 2.72065. The average price that 13.HK shares were previous bought at was HKD 2.99796. The current market price is -9.2% lower than average price they were purchased at. The value of the holding in 13.HK has increased by HKD 21,410 (USD $2,748) compared to the previous valuation of HUTCHMED (CHINA) LTD however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 182400.KQ - NKMAX LTD | HOLD | 0 @ KRW 3.98672 | KRW 0 | |
| 1877.HK - SHANGHAI JUNSHI BIOSCIENCES LTD H | HOLD | 0 @ HKD 2.93902 | HKD 0 | The current share valuation price of 1877.HK based on adjusted close was HKD 2.93902. The average price that 1877.HK shares were previous bought at was HKD 2.5435. The current market price is 15.6% higher than average price they were purchased at. The value of the holding in 1877.HK has increased by HKD 14,893 (USD $1,912) compared to the previous valuation of SHANGHAI JUNSHI BIOSCIENCES LTD H however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 207940.KS - SAMSUNG BIOLOGICS LTD | HOLD | 0 @ KRW 1186.25 | KRW 0 | The current share valuation price of 207940.KS based on adjusted close was KRW 1186.25. The average price that 207940.KS shares were previous bought at was KRW 800.215. The current market price is 48.2% higher than average price they were purchased at. The value of the holding in 207940.KS has increased by KRW 247,920 (USD $172) compared to the previous valuation of SAMSUNG BIOLOGICS LTD however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 2162.HK - KEYMED BIOSCIENCES INC | HOLD | 0 @ HKD 7.20626 | HKD 0 | The current share valuation price of 2162.HK based on adjusted close was HKD 7.20626. The average price that 2162.HK shares were previous bought at was HKD 5.38428. The current market price is 33.8% higher than average price they were purchased at. The value of the holding in 2162.HK has increased by HKD 76,853 (USD $9,865) compared to the previous valuation of KEYMED BIOSCIENCES INC however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 2252.HK - SHANGHAI MICROPORT MEDBOT CLASS H | HOLD | 0 @ HKD 3.18308 | HKD 0 | The current share valuation price of 2252.HK based on adjusted close was HKD 3.18308. The average price that 2252.HK shares were previous bought at was HKD 3.15899. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in 2252.HK has increased by HKD 21,354 (USD $2,741) compared to the previous valuation of SHANGHAI MICROPORT MEDBOT CLASS H however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 237690.KQ - ST Pharm Co.,Ltd. | HOLD | 0 @ KRW 85.7311 | KRW 0 | The current share valuation price of 237690.KQ based on adjusted close was KRW 85.7311. The average price that 237690.KQ shares were previous bought at was KRW 60.6995. The current market price is 41.2% higher than average price they were purchased at. The value of the holding in 237690.KQ has increased by KRW 95,236 (USD $66) compared to the previous valuation of ST Pharm Co.,Ltd. however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 298380.KQ - ABL Bio Inc. | HOLD | 0 @ KRW 146.809 | KRW 0 | The current share valuation price of 298380.KQ based on adjusted close was KRW 146.809. The average price that 298380.KQ shares were previous bought at was KRW 100.334. The current market price is 46.3% higher than average price they were purchased at. The value of the holding in 298380.KQ has increased by KRW 490,776 (USD $341) compared to the previous valuation of ABL Bio Inc. however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 302440.KS - SK BIOSCIENCE LTD | HOLD | 0 @ KRW 33.8977 | KRW 0 | The current share valuation price of 302440.KS based on adjusted close was KRW 33.8977. The average price that 302440.KS shares were previous bought at was KRW 36.1184. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in 302440.KS has increased by KRW 19,390 (USD $13) compared to the previous valuation of SK BIOSCIENCE LTD however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 326030.KS - SK BIOPHARMACEUTICALS LTD | HOLD | 0 @ KRW 87.2546 | KRW 0 | The current share valuation price of 326030.KS based on adjusted close was KRW 87.2546. The average price that 326030.KS shares were previous bought at was KRW 78.0703. The current market price is 11.8% higher than average price they were purchased at. The value of the holding in 326030.KS has increased by KRW 69,494 (USD $48) compared to the previous valuation of SK BIOPHARMACEUTICALS LTD however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 328130.KQ - Lunit Inc. | HOLD | 0 @ KRW 30.1236 | KRW 0 | The current share valuation price of 328130.KQ based on adjusted close was KRW 30.1236. The average price that 328130.KQ shares were previous bought at was KRW 36.1354. The current market price is -16.6% lower than average price they were purchased at. The value of the holding in 328130.KQ has fallen by KRW 11,153 (USD $8) compared to the previous valuation of Lunit Inc. |
| 3933.HK - THE UNITED LABORATORIES INTERNATIO | HOLD | 0 @ HKD 1.54016 | HKD 0 | The current share valuation price of 3933.HK based on adjusted close was HKD 1.54016. The average price that 3933.HK shares were previous bought at was HKD 1.66691. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in 3933.HK has increased by HKD 42,085 (USD $5,402) compared to the previous valuation of THE UNITED LABORATORIES INTERNATIO however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 30.5713 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 30.5713. The average price that 4523.T shares were previous bought at was JPY 28.5706. The current market price is 7.0% higher than average price they were purchased at. The value of the holding in 4523.T has increased by JPY 285,169 (USD $1,816) compared to the previous valuation of Eisai Co., Ltd. however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 4549.T - Eiken Chemical Co., Ltd. | HOLD | 0 @ JPY 15.3463 | JPY 0 | The current share valuation price of 4549.T based on adjusted close was JPY 15.3463. The average price that 4549.T shares were previous bought at was JPY 13.7463. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in 4549.T has fallen by JPY 733 (USD $5) compared to the previous valuation of Eiken Chemical Co., Ltd. |
| 4587.T - PeptiDream Inc. | HOLD | 0 @ JPY 10.3522 | JPY 0 | The current share valuation price of 4587.T based on adjusted close was JPY 10.3522. The average price that 4587.T shares were previous bought at was JPY 11.0208. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in 4587.T has fallen by JPY 28,589 (USD $182) compared to the previous valuation of PeptiDream Inc. |
| 4887.T - Sawai Group Holdings Co., Ltd. | HOLD | 0 @ JPY 15.11 | JPY 0 | The current share valuation price of 4887.T based on adjusted close was JPY 15.11. The average price that 4887.T shares were previous bought at was JPY 13.3528. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in 4887.T has increased by JPY 5,279 (USD $34) compared to the previous valuation of Sawai Group Holdings Co., Ltd. however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 4974.T - Takara Bio Inc. | HOLD | 0 @ JPY 5.07712 | JPY 0 | The current share valuation price of 4974.T based on adjusted close was JPY 5.07712. The average price that 4974.T shares were previous bought at was JPY 5.70398. The current market price is -11.0% lower than average price they were purchased at. JPY 0 (USD $0) compared to the previous valuation of Takara Bio Inc. however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.79979 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.79979. The average price that 6869.T shares were previous bought at was JPY 14.7177. The current market price is -33.4% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 32,219 (USD $205) compared to the previous valuation of Sysmex Corporation |
| 6951.T - JEOL Ltd. | HOLD | 0 @ JPY 32.1551 | JPY 0 | The current share valuation price of 6951.T based on adjusted close was JPY 32.1551. The average price that 6951.T shares were previous bought at was JPY 33.0007. The current market price is -2.6% lower than average price they were purchased at. The value of the holding in 6951.T has increased by JPY 1,576 (USD $10) compared to the previous valuation of JEOL Ltd. however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 7575.T - Japan Lifeline Co., Ltd. | HOLD | 0 @ JPY 10.3267 | JPY 0 | The current share valuation price of 7575.T based on adjusted close was JPY 10.3267. The average price that 7575.T shares were previous bought at was JPY 10.1362. The current market price is 1.9% higher than average price they were purchased at. The value of the holding in 7575.T has increased by JPY 18,146 (USD $116) compared to the previous valuation of Japan Lifeline Co., Ltd. however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 7701.T - Shimadzu Corporation | HOLD | 0 @ JPY 26.8608 | JPY 0 | The current share valuation price of 7701.T based on adjusted close was JPY 26.8608. The average price that 7701.T shares were previous bought at was JPY 26.482. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in 7701.T has increased by JPY 86,636 (USD $552) compared to the previous valuation of Shimadzu Corporation however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 7747.T - Asahi Intecc Co., Ltd. | HOLD | 0 @ JPY 18.9546 | JPY 0 | The current share valuation price of 7747.T based on adjusted close was JPY 18.9546. The average price that 7747.T shares were previous bought at was JPY 16.9935. The current market price is 11.5% higher than average price they were purchased at. The value of the holding in 7747.T has increased by JPY 57,987 (USD $369) compared to the previous valuation of Asahi Intecc Co., Ltd. however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| 9995.HK - REMEGEN LTD H | HOLD | 0 @ HKD 10.2121 | HKD 0 | The current share valuation price of 9995.HK based on adjusted close was HKD 10.2121. The average price that 9995.HK shares were previous bought at was HKD 9.68574. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in 9995.HK has increased by HKD 153,621 (USD $19,719) compared to the previous valuation of REMEGEN LTD H however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 142.93 | USD 0 | The current share valuation price of A based on adjusted close was USD 142.93. The average price that A shares were previous bought at was USD 123.184. The current market price is 16.0% higher than average price they were purchased at. The value of the holding in A has increased by USD 617,495 compared to the previous valuation of Agilent Technologies Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 220.18 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 220.18. The average price that ABBV shares were previous bought at was USD 204.991. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 719,992 compared to the previous valuation of AbbVie Inc |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.43 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.43. The average price that ABCL shares were previous bought at was USD 3.60785. The current market price is -4.9% lower than average price they were purchased at. USD 0 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 126.45 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 126.45. The average price that ABT shares were previous bought at was USD 124.68. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in ABT has increased by USD 251,794 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 26.15 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 26.15. The average price that ACAD shares were previous bought at was USD 20.3943. The current market price is 28.2% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 20,985 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 61.83 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 61.83. The average price that ACLX shares were previous bought at was USD 64.8526. The current market price is -4.7% lower than average price they were purchased at. The value of the holding in ACLX has fallen by USD 76,510 compared to the previous valuation of Arcellx Inc |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 16.17 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 16.17. The average price that ADPT shares were previous bought at was USD 7.03745. The current market price is 129.8% higher than average price they were purchased at. The value of the holding in ADPT has increased by USD 47,553 compared to the previous valuation of Adaptive Biotechnologies Corp however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 28 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 28. The average price that ALKS shares were previous bought at was USD 30.1849. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in ALKS has fallen by USD 52,378 compared to the previous valuation of Alkermes Plc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 320.72 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 320.72. The average price that AMGN shares were previous bought at was USD 299.092. The current market price is 7.2% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 352,422 compared to the previous valuation of Amgen Inc |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 11.39 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 11.39. The average price that AMLX shares were previous bought at was USD 13.2037. The current market price is -13.7% lower than average price they were purchased at. The value of the holding in AMLX has fallen by USD 2,663 compared to the previous valuation of Amylyx Pharmaceuticals Inc |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 43.2 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 43.2. The average price that ANAB shares were previous bought at was USD 24.2251. The current market price is 78.3% higher than average price they were purchased at. The value of the holding in ANAB has fallen by USD 45,268 compared to the previous valuation of AnaptysBio Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.37 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.37. The average price that ARCT shares were previous bought at was USD 12.3242. The current market price is -48.3% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 3,130 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 11.17 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 11.17. The average price that ARVN shares were previous bought at was USD 11.3713. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in ARVN has fallen by USD 25,396 compared to the previous valuation of Arvinas Inc |
| ASTH - Astrana Health Inc | HOLD | 0 @ USD 27.4 | USD 0 | The current share valuation price of ASTH based on adjusted close was USD 27.4. The average price that ASTH shares were previous bought at was USD 26.4973. The current market price is 3.4% higher than average price they were purchased at. The value of the holding in ASTH has increased by USD 105,764 compared to the previous valuation of Astrana Health Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| ATRC - AtriCure Inc | HOLD | 0 @ USD 40.52 | USD 0 | The current share valuation price of ATRC based on adjusted close was USD 40.52. The average price that ATRC shares were previous bought at was USD 33.6752. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in ATRC has increased by USD 74,275 compared to the previous valuation of AtriCure Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 15.3 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 15.3. The average price that AUPH shares were previous bought at was USD 11.6813. The current market price is 31.0% higher than average price they were purchased at. The value of the holding in AUPH has fallen by USD 7,976 compared to the previous valuation of Aurinia Pharmaceuticals Inc |
| AXGN - Axogen Inc | HOLD | 0 @ USD 31.76 | USD 0 | The current share valuation price of AXGN based on adjusted close was USD 31.76. The average price that AXGN shares were previous bought at was USD 18.5561. The current market price is 71.2% higher than average price they were purchased at. The value of the holding in AXGN has increased by USD 40,173 compared to the previous valuation of Axogen Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 171.49 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 171.49. The average price that AXSM shares were previous bought at was USD 124.635. The current market price is 37.6% higher than average price they were purchased at. The value of the holding in AXSM has fallen by USD 336,320 compared to the previous valuation of Axsome Therapeutics Inc |
| BAVA.CO - | HOLD | 0 @ DKK 30.2266 | DKK 0 | The current share valuation price of BAVA.CO based on adjusted close was DKK 30.2266. The average price that BAVA.CO shares were previous bought at was DKK 25.5909. The current market price is 18.1% higher than average price they were purchased at. The value of the holding in BAVA.CO has fallen by DKK 10,303 (USD $1,614) compared to the previous valuation of |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.41 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.41. The average price that BCRX shares were previous bought at was USD 7.7452. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in BCRX has fallen by USD 23,279 compared to the previous valuation of BioCryst Pharmaceuticals Inc |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 26.84 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 26.84. The average price that BEAM shares were previous bought at was USD 18.7837. The current market price is 42.9% higher than average price they were purchased at. The value of the holding in BEAM has fallen by USD 36,814 compared to the previous valuation of Beam Therapeutics Inc |
| BIIB - Biogen Inc | HOLD | 0 @ USD 174.63 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 174.63. The average price that BIIB shares were previous bought at was USD 131.648. The current market price is 32.6% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 351,841 compared to the previous valuation of Biogen Inc |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 131.324 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 131.324. The average price that BIM.PA shares were previous bought at was EUR 122.646. The current market price is 7.1% higher than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 156,782 (USD $183,508) compared to the previous valuation of BioMerieux however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| BIO - Bio-Rad Laboratories Inc | HOLD | 0 @ USD 322.34 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 322.34. The average price that BIO shares were previous bought at was USD 290.943. The current market price is 10.8% higher than average price they were purchased at. The value of the holding in BIO has increased by USD 439,006 compared to the previous valuation of Bio-Rad Laboratories Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| BIO - Biotest Aktiengesellschaft | HOLD | 0 @ USD 322.34 | USD 0 | The current share valuation price of BIO based on adjusted close was USD 322.34. The average price that BIO shares were previous bought at was USD 290.943. The current market price is 10.8% higher than average price they were purchased at. The value of the holding in BIO has increased by USD 439,006 compared to the previous valuation of Biotest Aktiengesellschaft however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| BIOA-B.ST - | HOLD | 0 @ SEK 33.6445 | SEK 0 | The current share valuation price of BIOA-B.ST based on adjusted close was SEK 33.6445. The average price that BIOA-B.ST shares were previous bought at was SEK 30.1726. The current market price is 11.5% higher than average price they were purchased at. The value of the holding in BIOA-B.ST has fallen by SEK 7,547 (USD $818) compared to the previous valuation of |
| BLFS - BioLife Solutions Inc | HOLD | 0 @ USD 25.31 | USD 0 | The current share valuation price of BLFS based on adjusted close was USD 25.31. The average price that BLFS shares were previous bought at was USD 25.5106. The current market price is -0.8% lower than average price they were purchased at. The value of the holding in BLFS has increased by USD 80,054 compared to the previous valuation of BioLife Solutions Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 53.06 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 53.06. The average price that BMY shares were previous bought at was USD 53.3789. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in BMY has fallen by USD 119,623 compared to the previous valuation of Bloomsbury Publishing Plc |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 95.48 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 95.48. The average price that BSX shares were previous bought at was USD 97.348. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 115,832 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 95.48 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 95.48. The average price that BSX shares were previous bought at was USD 97.348. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 115,832 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| CDNA - Caredx Inc | HOLD | 0 @ USD 19.81 | USD 0 | The current share valuation price of CDNA based on adjusted close was USD 19.81. The average price that CDNA shares were previous bought at was USD 19.2054. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in CDNA has increased by USD 41,457 compared to the previous valuation of Caredx Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| CERT - Certara Inc | HOLD | 0 @ USD 9.04 | USD 0 | The current share valuation price of CERT based on adjusted close was USD 9.04. The average price that CERT shares were previous bought at was USD 10.3575. The current market price is -12.7% lower than average price they were purchased at. The value of the holding in CERT has increased by USD 42,117 compared to the previous valuation of Certara Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 40.04 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 40.04. The average price that CGON shares were previous bought at was USD 41.5514. The current market price is -3.6% lower than average price they were purchased at. The value of the holding in CGON has fallen by USD 130,468 compared to the previous valuation of CG Oncology, Inc. Common stock |
| CHEMM.CO - | HOLD | 0 @ DKK 107.023 | DKK 0 | The current share valuation price of CHEMM.CO based on adjusted close was DKK 107.023. The average price that CHEMM.CO shares were previous bought at was DKK 79.3096. The current market price is 34.9% higher than average price they were purchased at. The value of the holding in CHEMM.CO has increased by DKK 18,931 (USD $2,966) compared to the previous valuation of however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| CPRX - Catalyst Pharmaceuticals Inc | HOLD | 0 @ USD 22.8 | USD 0 | The current share valuation price of CPRX based on adjusted close was USD 22.8. The average price that CPRX shares were previous bought at was USD 22.4625. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in CPRX has fallen by USD 51,912 compared to the previous valuation of Catalyst Pharmaceuticals Inc |
| CRL - Creightons Plc | HOLD | 0 @ USD 208.32 | USD 0 | The current share valuation price of CRL based on adjusted close was USD 208.32. The average price that CRL shares were previous bought at was USD 170.17. The current market price is 22.4% higher than average price they were purchased at. The value of the holding in CRL has increased by USD 352,171 compared to the previous valuation of Creightons Plc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| CRVL - CorVel Corp | HOLD | 0 @ USD 68.14 | USD 0 | The current share valuation price of CRVL based on adjusted close was USD 68.14. The average price that CRVL shares were previous bought at was USD 111.286. The current market price is -38.8% lower than average price they were purchased at. The value of the holding in CRVL has increased by USD 85,651 compared to the previous valuation of CorVel Corp however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 39 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 39. The average price that CSTL shares were previous bought at was USD 21.8554. The current market price is 78.4% higher than average price they were purchased at. The value of the holding in CSTL has increased by USD 15,994 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| CTKB - Cytek Biosciences Inc | HOLD | 0 @ USD 5.21 | USD 0 | The current share valuation price of CTKB based on adjusted close was USD 5.21. The average price that CTKB shares were previous bought at was USD 5.6893. The current market price is -8.4% lower than average price they were purchased at. The value of the holding in CTKB has increased by USD 45,798 compared to the previous valuation of Cytek Biosciences Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 8.55 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 8.55. The average price that DAWN shares were previous bought at was USD 8.51758. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in DAWN has fallen by USD 27,523 compared to the previous valuation of Day One Biopharmaceuticals Inc |
| DHR - Danaher Corporation | HOLD | 0 @ USD 235.36 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 235.36. The average price that DHR shares were previous bought at was USD 201.106. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 365,815 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 235.36 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 235.36. The average price that DHR shares were previous bought at was USD 201.106. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 365,815 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| DIA.MI - DiaSorin SpA | HOLD | 0 @ EUR 81.5101 | EUR 0 | The current share valuation price of DIA.MI based on adjusted close was EUR 81.5101. The average price that DIA.MI shares were previous bought at was EUR 61.334. The current market price is 32.9% higher than average price they were purchased at. The value of the holding in DIA.MI has increased by EUR 36,525 (USD $42,751) compared to the previous valuation of DiaSorin SpA however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 15.41 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 15.41. The average price that DVAX shares were previous bought at was USD 13.5721. The current market price is 13.5% higher than average price they were purchased at. The value of the holding in DVAX has increased by USD 4,433 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 67.65 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 67.65. The average price that DXCM shares were previous bought at was USD 78.4278. The current market price is -13.7% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 195,563 compared to the previous valuation of DexCom Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| DYVOX.ST - | HOLD | 0 @ SEK 10.6552 | SEK 0 | The current share valuation price of DYVOX.ST based on adjusted close was SEK 10.6552. The average price that DYVOX.ST shares were previous bought at was SEK 7.40257. The current market price is 43.9% higher than average price they were purchased at. The value of the holding in DYVOX.ST has fallen by SEK 8,040 (USD $871) compared to the previous valuation of |
| EKTA-B.ST - | HOLD | 0 @ SEK 6.1888 | SEK 0 | The current share valuation price of EKTA-B.ST based on adjusted close was SEK 6.1888. The average price that EKTA-B.ST shares were previous bought at was SEK 5.66491. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in EKTA-B.ST has increased by SEK 7,859 (USD $852) compared to the previous valuation of however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| EMBC - Embecta Corp | HOLD | 0 @ USD 11.62 | USD 0 | The current share valuation price of EMBC based on adjusted close was USD 11.62. The average price that EMBC shares were previous bought at was USD 12.8193. The current market price is -9.4% lower than average price they were purchased at. The value of the holding in EMBC has fallen by USD 2,770 compared to the previous valuation of Embecta Corp |
| EUZ.DE - Eckert & Ziegler SE | HOLD | 0 @ EUR 17.6153 | EUR 0 | The current share valuation price of EUZ.DE based on adjusted close was EUR 17.6153. The average price that EUZ.DE shares were previous bought at was EUR 18.6179. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in EUZ.DE has fallen by EUR 1,230 (USD $1,440) compared to the previous valuation of Eckert & Ziegler SE |
| EVH - Evolent Health Inc | HOLD | 0 @ USD 3.95 | USD 0 | The current share valuation price of EVH based on adjusted close was USD 3.95. The average price that EVH shares were previous bought at was USD 9.2746. The current market price is -57.4% lower than average price they were purchased at. The value of the holding in EVH has increased by USD 7,646 compared to the previous valuation of Evolent Health Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| EVT.DE - Evotec SE | HOLD | 0 @ EUR 6.44918 | EUR 0 | The current share valuation price of EVT.DE based on adjusted close was EUR 6.44918. The average price that EVT.DE shares were previous bought at was EUR 6.56011. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in EVT.DE has fallen by EUR 7,219 (USD $8,450) compared to the previous valuation of Evotec SE |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 84.17 | USD 0 | The current share valuation price of EW based on adjusted close was USD 84.17. The average price that EW shares were previous bought at was USD 75.1337. The current market price is 12.0% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 228,693 compared to the previous valuation of Edwards Lifesciences Corp |
| EXAS - EXACT Sciences Corporation | HOLD | 0 @ USD 101.61 | USD 0 | The current share valuation price of EXAS based on adjusted close was USD 101.61. The average price that EXAS shares were previous bought at was USD 66.1767. The current market price is 53.5% higher than average price they were purchased at. The value of the holding in EXAS has fallen by USD 29,802 compared to the previous valuation of EXACT Sciences Corporation |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 42.4 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 42.4. The average price that EXEL shares were previous bought at was USD 38.8638. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in EXEL has fallen by USD 391,074 compared to the previous valuation of Exelixis Inc |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 16.62 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 16.62. The average price that FTRE shares were previous bought at was USD 10.8459. The current market price is 53.2% higher than average price they were purchased at. The value of the holding in FTRE has fallen by USD 21,132 compared to the previous valuation of Fortrea Holdings Inc. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 101.87 | USD 0 | The current share valuation price of GH based on adjusted close was USD 101.87. The average price that GH shares were previous bought at was USD 60.3035. The current market price is 68.9% higher than average price they were purchased at. The value of the holding in GH has increased by USD 19,573 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 118.3 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 118.3. The average price that GILD shares were previous bought at was USD 108.874. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 447,948 compared to the previous valuation of Guild Esports Plc |
| GLPG.AS - Galapagos NV | HOLD | 0 @ EUR 31.9533 | EUR 0 | The current share valuation price of GLPG.AS based on adjusted close was EUR 31.9533. The average price that GLPG.AS shares were previous bought at was EUR 29.4493. The current market price is 8.5% higher than average price they were purchased at. The value of the holding in GLPG.AS has fallen by EUR 51,737 (USD $60,556) compared to the previous valuation of Galapagos NV |
| GMAB.CO - | HOLD | 0 @ DKK 314.958 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 314.958. The average price that GMAB.CO shares were previous bought at was DKK 226.549. The current market price is 39.0% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 53,763 (USD $8,425) compared to the previous valuation of |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 24.5831 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 24.5831. The average price that GSK.L shares were previous bought at was GBP 19.8054. The current market price is 24.1% higher than average price they were purchased at. The value of the holding in GSK.L has fallen by GBP 104,175 (USD $139,990) compared to the previous valuation of GlaxoSmithKline PLC |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 71.2 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 71.2. The average price that HALO shares were previous bought at was USD 61.4979. The current market price is 15.8% higher than average price they were purchased at. The value of the holding in HALO has increased by USD 133,277 compared to the previous valuation of Halozyme Therapeutics Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| HLUN-B.CO - | HOLD | 0 @ DKK 6.67523 | DKK 0 | The current share valuation price of HLUN-B.CO based on adjusted close was DKK 6.67523. The average price that HLUN-B.CO shares were previous bought at was DKK 6.26175. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in HLUN-B.CO has fallen by DKK 30,449 (USD $4,771) compared to the previous valuation of |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.75 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.75. The average price that HOLX shares were previous bought at was USD 66.7263. The current market price is 12.0% higher than average price they were purchased at. The value of the holding in HOLX has increased by USD 43,588 compared to the previous valuation of Hologic Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 36.75 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 36.75. The average price that HRMY shares were previous bought at was USD 33.6514. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in HRMY has fallen by USD 34,728 compared to the previous valuation of Harmony Biosciences Holdings |
| IART - Integra LifeSciences Holdings | HOLD | 0 @ USD 12.56 | USD 0 | The current share valuation price of IART based on adjusted close was USD 12.56. The average price that IART shares were previous bought at was USD 15.8779. The current market price is -20.9% lower than average price they were purchased at. The value of the holding in IART has increased by USD 48,095 compared to the previous valuation of Integra LifeSciences Holdings however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.08 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.08. The average price that IBRX shares were previous bought at was USD 2.80572. The current market price is -25.9% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 16,552 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 34.94 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 34.94. The average price that IDYA shares were previous bought at was USD 24.0067. The current market price is 45.5% higher than average price they were purchased at. The value of the holding in IDYA has increased by USD 115,856 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 141.33 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 141.33. The average price that ILMN shares were previous bought at was USD 96.7199. The current market price is 46.1% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 1,185,588 compared to the previous valuation of Illumina Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.45 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.45. The average price that IOVA shares were previous bought at was USD 2.41741. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in IOVA has fallen by USD 23,342 compared to the previous valuation of Iovance Biotherapeutics Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 136.943 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 136.943. The average price that IPN.PA shares were previous bought at was EUR 123.827. The current market price is 10.6% higher than average price they were purchased at. The value of the holding in IPN.PA has increased by EUR 22,447 (USD $26,273) compared to the previous valuation of Ipsen SA however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 234.59 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 234.59. The average price that IQV shares were previous bought at was USD 164.563. The current market price is 42.6% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 862,383 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 566.38 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 566.38. The average price that ISRG shares were previous bought at was USD 539.322. The current market price is 5.0% higher than average price they were purchased at. The value of the holding in ISRG has increased by USD 124,154 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 13.75 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 13.75. The average price that JANX shares were previous bought at was USD 24.6116. The current market price is -44.1% lower than average price they were purchased at. The value of the holding in JANX has increased by USD 6,902 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 204.31 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 204.31. The average price that JNJ shares were previous bought at was USD 176.223. The current market price is 15.9% higher than average price they were purchased at. The value of the holding in JNJ has fallen by USD 290,378 compared to the previous valuation of Johnson & Johnson |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 41.06 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 41.06. The average price that KNSA shares were previous bought at was USD 40.3852. The current market price is 1.7% higher than average price they were purchased at. The value of the holding in KNSA has fallen by USD 49,360 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 9.54 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 9.54. The average price that KURA shares were previous bought at was USD 10.609. The current market price is -10.1% lower than average price they were purchased at. The value of the holding in KURA has fallen by USD 74,861 compared to the previous valuation of Kura Oncology Inc |
| LAB - Standard Biotools Inc | HOLD | 0 @ USD 1.32 | USD 0 | The current share valuation price of LAB based on adjusted close was USD 1.32. The average price that LAB shares were previous bought at was USD 1.36709. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in LAB has increased by USD 20,814 compared to the previous valuation of Standard Biotools Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 192.03 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 192.03. The average price that LGND shares were previous bought at was USD 127.891. The current market price is 50.2% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 44,732 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| LIVN - LivaNova PLC | HOLD | 0 @ USD 63.23 | USD 0 | The current share valuation price of LIVN based on adjusted close was USD 63.23. The average price that LIVN shares were previous bought at was USD 51.0298. The current market price is 23.9% higher than average price they were purchased at. The value of the holding in LIVN has increased by USD 171,621 compared to the previous valuation of LivaNova PLC however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| LNTH - Lantheus Holdings Inc | HOLD | 0 @ USD 68.98 | USD 0 | The current share valuation price of LNTH based on adjusted close was USD 68.98. The average price that LNTH shares were previous bought at was USD 76.5173. The current market price is -9.9% lower than average price they were purchased at. The value of the holding in LNTH has increased by USD 142,843 compared to the previous valuation of Lantheus Holdings Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| MDT - Medtronic PLC | HOLD | 0 @ USD 97.36 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 97.36. The average price that MDT shares were previous bought at was USD 90.9719. The current market price is 7.0% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 222,561 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 586.83 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 586.83. The average price that MEDP shares were previous bought at was USD 400.922. The current market price is 46.4% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 461,272 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| MMS - LYXETFETUSITETFP | HOLD | 0 @ USD 89.79 | USD 0 | The current share valuation price of MMS based on adjusted close was USD 89.79. The average price that MMS shares were previous bought at was USD 77.1172. The current market price is 16.4% higher than average price they were purchased at. The value of the holding in MMS has increased by USD 227,878 compared to the previous valuation of LYXETFETUSITETFP however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 107.44 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 107.44. The average price that MRK shares were previous bought at was USD 81.474. The current market price is 31.9% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 181,862 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 107.44 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 107.44. The average price that MRK shares were previous bought at was USD 81.474. The current market price is 31.9% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 181,862 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 32.17 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 32.17. The average price that MRNA shares were previous bought at was USD 26.0348. The current market price is 23.6% higher than average price they were purchased at. The value of the holding in MRNA has increased by USD 615,514 compared to the previous valuation of Moderna Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.79 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.79. The average price that MRVI shares were previous bought at was USD 2.98184. The current market price is 27.1% higher than average price they were purchased at. The value of the holding in MRVI has increased by USD 61,158 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| MYGN - Myriad Genetics Inc | HOLD | 0 @ USD 6.14 | USD 0 | The current share valuation price of MYGN based on adjusted close was USD 6.14. The average price that MYGN shares were previous bought at was USD 8.54619. The current market price is -28.2% lower than average price they were purchased at. USD 0 compared to the previous valuation of Myriad Genetics Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 135.99 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 135.99. The average price that NBIX shares were previous bought at was USD 128.58. The current market price is 5.8% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 552,145 compared to the previous valuation of Neurocrine Biosciences Inc |
| NEOG - Neogen Corporation | HOLD | 0 @ USD 7.26 | USD 0 | The current share valuation price of NEOG based on adjusted close was USD 7.26. The average price that NEOG shares were previous bought at was USD 9.86113. The current market price is -26.4% lower than average price they were purchased at. The value of the holding in NEOG has increased by USD 67,265 compared to the previous valuation of Neogen Corporation however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| NEU.AX - | HOLD | 0 @ AUD 12.7596 | AUD 0 | The current share valuation price of NEU.AX based on adjusted close was AUD 12.7596. The average price that NEU.AX shares were previous bought at was AUD 8.98382. The current market price is 42.0% higher than average price they were purchased at. The value of the holding in NEU.AX has increased by AUD 17,680 (USD $11,817) compared to the previous valuation of however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 237.42 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 237.42. The average price that NTRA shares were previous bought at was USD 181.943. The current market price is 30.5% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 776,044 compared to the previous valuation of Natera Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| NUVB - Nuvation Bio Inc | HOLD | 0 @ USD 8.59 | USD 0 | The current share valuation price of NUVB based on adjusted close was USD 8.59. The average price that NUVB shares were previous bought at was USD 7.97749. The current market price is 7.7% higher than average price they were purchased at. The value of the holding in NUVB has increased by USD 3,019 compared to the previous valuation of Nuvation Bio Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 7.25 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.25. The average price that NVAX shares were previous bought at was USD 6.53355. The current market price is 11.0% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 21,778 compared to the previous valuation of Novavax Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 7.25 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.25. The average price that NVAX shares were previous bought at was USD 6.53355. The current market price is 11.0% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 21,778 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 13.77 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 13.77. The average price that NVCR shares were previous bought at was USD 16.2788. The current market price is -15.4% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 82,159 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| ONT.L - Oxford Nanopore Technologies Ltd | HOLD | 0 @ GBP 1.75546 | GBP 0 | The current share valuation price of ONT.L based on adjusted close was GBP 1.75546. The average price that ONT.L shares were previous bought at was GBP 1.72755. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in ONT.L has increased by GBP 18,931 (USD $25,439) compared to the previous valuation of Oxford Nanopore Technologies Ltd however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.98 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.98. The average price that PACB shares were previous bought at was USD 1.38552. The current market price is 42.9% higher than average price they were purchased at. The value of the holding in PACB has increased by USD 50,808 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.17 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.17. The average price that PFE shares were previous bought at was USD 24.3851. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in PFE has fallen by USD 6,149 compared to the previous valuation of Pfizer Inc |
| PHARM.AS - Pharming Group NV | HOLD | 0 @ EUR 1.6714 | EUR 0 | The current share valuation price of PHARM.AS based on adjusted close was EUR 1.6714. The average price that PHARM.AS shares were previous bought at was EUR 0.920936. The current market price is 81.5% higher than average price they were purchased at. The value of the holding in PHARM.AS has fallen by EUR 40,049 (USD $46,876) compared to the previous valuation of Pharming Group NV |
| PHM.MC - Pharma Mar SA | HOLD | 0 @ EUR 87.6667 | EUR 0 | The current share valuation price of PHM.MC based on adjusted close was EUR 87.6667. The average price that PHM.MC shares were previous bought at was EUR 87.2276. The current market price is 0.5% higher than average price they were purchased at. The value of the holding in PHM.MC has fallen by EUR 34,574 (USD $40,468) compared to the previous valuation of Pharma Mar SA |
| PME.AX - | HOLD | 0 @ AUD 144.434 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 144.434. The average price that PME.AX shares were previous bought at was AUD 163.513. The current market price is -11.7% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 304,570 (USD $203,572) compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 283.51 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 283.51. The average price that PODD shares were previous bought at was USD 283.102. The current market price is 0.1% higher than average price they were purchased at. The value of the holding in PODD has increased by USD 29,515 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 276.92 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 276.92. The average price that PRAX shares were previous bought at was USD 204.552. The current market price is 35.4% higher than average price they were purchased at. The value of the holding in PRAX has fallen by USD 235,957 compared to the previous valuation of Praxis Precision Medicines Inc |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 76.76 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 76.76. The average price that PTCT shares were previous bought at was USD 59.2985. The current market price is 29.4% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 1,926 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| QDEL - Quidel Corporation | HOLD | 0 @ USD 30.06 | USD 0 | The current share valuation price of QDEL based on adjusted close was USD 30.06. The average price that QDEL shares were previous bought at was USD 29.4465. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in QDEL has increased by USD 106,281 compared to the previous valuation of Quidel Corporation however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| RCUS - Arcus Biosciences Inc | HOLD | 0 @ USD 21.77 | USD 0 | The current share valuation price of RCUS based on adjusted close was USD 21.77. The average price that RCUS shares were previous bought at was USD 10.304. The current market price is 111.3% higher than average price they were purchased at. The value of the holding in RCUS has fallen by USD 139,593 compared to the previous valuation of Arcus Biosciences Inc |
| RGEN - Repligen Corporation | HOLD | 0 @ USD 169.44 | USD 0 | The current share valuation price of RGEN based on adjusted close was USD 169.44. The average price that RGEN shares were previous bought at was USD 148.012. The current market price is 14.5% higher than average price they were purchased at. The value of the holding in RGEN has increased by USD 324,635 compared to the previous valuation of Repligen Corporation however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 13.4 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 13.4. The average price that RGNX shares were previous bought at was USD 8.80724. The current market price is 52.1% higher than average price they were purchased at. The value of the holding in RGNX has fallen by USD 9,072 compared to the previous valuation of Regenxbio Inc |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 7.86 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 7.86. The average price that RLAY shares were previous bought at was USD 7.0368. The current market price is 11.7% higher than average price they were purchased at. The value of the holding in RLAY has fallen by USD 57,403 compared to the previous valuation of Relay Therapeutics Inc |
| RO.SW - | HOLD | 0 @ CHF 419.938 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 419.938. The average price that RO.SW shares were previous bought at was CHF 371.765. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in RO.SW has fallen by CHF 7,394 (USD $9,319) compared to the previous valuation of |
| RVTY - Revvity Inc. | HOLD | 0 @ USD 102.06 | USD 0 | The current share valuation price of RVTY based on adjusted close was USD 102.06. The average price that RVTY shares were previous bought at was USD 99.3535. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in RVTY has increased by USD 560,088 compared to the previous valuation of Revvity Inc. however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.37 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.37. The average price that RXRX shares were previous bought at was USD 5.07964. The current market price is -14.0% lower than average price they were purchased at. The value of the holding in RXRX has increased by USD 84,013 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 101.86 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 101.86. The average price that RYTM shares were previous bought at was USD 71.9834. The current market price is 41.5% higher than average price they were purchased at. The value of the holding in RYTM has fallen by USD 222,233 compared to the previous valuation of Rhythm Pharmaceuticals Inc |
| SDGR - Schrodinger Inc | HOLD | 0 @ USD 18.5 | USD 0 | The current share valuation price of SDGR based on adjusted close was USD 18.5. The average price that SDGR shares were previous bought at was USD 20.5088. The current market price is -9.8% lower than average price they were purchased at. The value of the holding in SDGR has increased by USD 38,601 compared to the previous valuation of Schrodinger Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| SECT-B.ST - | HOLD | 0 @ SEK 25.6898 | SEK 0 | The current share valuation price of SECT-B.ST based on adjusted close was SEK 25.6898. The average price that SECT-B.ST shares were previous bought at was SEK 27.9755. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in SECT-B.ST has fallen by SEK 64,665 (USD $7,009) compared to the previous valuation of |
| SFZN.SW - | HOLD | 0 @ CHF 94.1458 | CHF 0 | The current share valuation price of SFZN.SW based on adjusted close was CHF 94.1458. The average price that SFZN.SW shares were previous bought at was CHF 123.442. The current market price is -23.7% lower than average price they were purchased at. The value of the holding in SFZN.SW has fallen by CHF 11,659 (USD $14,695) compared to the previous valuation of |
| SLP - Sylvania Platinum Limited | HOLD | 0 @ USD 19.2 | USD 0 | The current share valuation price of SLP based on adjusted close was USD 19.2. The average price that SLP shares were previous bought at was USD 25.9621. The current market price is -26.0% lower than average price they were purchased at. The value of the holding in SLP has increased by USD 19,763 compared to the previous valuation of Sylvania Platinum Limited however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 21.07 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 21.07. The average price that SRPT shares were previous bought at was USD 44.2759. The current market price is -52.4% lower than average price they were purchased at. The value of the holding in SRPT has fallen by USD 28,981 compared to the previous valuation of Sarepta Therapeutics Inc |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 297.88 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 297.88. The average price that SRT3.DE shares were previous bought at was EUR 253.196. The current market price is 17.6% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 204,815 (USD $239,729) compared to the previous valuation of Sartorius AG however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 32.55 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 32.55. The average price that STOK shares were previous bought at was USD 13.4707. The current market price is 141.6% higher than average price they were purchased at. The value of the holding in STOK has increased by USD 111,091 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 49.4 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 49.4. The average price that SUPN shares were previous bought at was USD 39.2959. The current market price is 25.7% higher than average price they were purchased at. The value of the holding in SUPN has fallen by USD 4,807 compared to the previous valuation of Supernus Pharmaceuticals Inc |
| TECH - Bio-Techne Corp | HOLD | 0 @ USD 63.03 | USD 0 | The current share valuation price of TECH based on adjusted close was USD 63.03. The average price that TECH shares were previous bought at was USD 59.3335. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in TECH has increased by USD 643,948 compared to the previous valuation of Bio-Techne Corp however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| TECN.SW - | HOLD | 0 @ CHF 167.118 | CHF 0 | The current share valuation price of TECN.SW based on adjusted close was CHF 167.118. The average price that TECN.SW shares were previous bought at was CHF 195.138. The current market price is -14.4% lower than average price they were purchased at. The value of the holding in TECN.SW has increased by CHF 69,907 (USD $88,111) compared to the previous valuation of however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| TGTX - TG Therapeutics Inc | HOLD | 0 @ USD 29.9 | USD 0 | The current share valuation price of TGTX based on adjusted close was USD 29.9. The average price that TGTX shares were previous bought at was USD 33.1054. The current market price is -9.7% lower than average price they were purchased at. The value of the holding in TGTX has increased by USD 108,864 compared to the previous valuation of TG Therapeutics Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 611.2 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 611.2. The average price that TMO shares were previous bought at was USD 423.975. The current market price is 44.2% higher than average price they were purchased at. The value of the holding in TMO has increased by USD 673,756 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| TNDM - Tandem Diabetes Care Inc | HOLD | 0 @ USD 23.15 | USD 0 | The current share valuation price of TNDM based on adjusted close was USD 23.15. The average price that TNDM shares were previous bought at was USD 21.1819. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in TNDM has increased by USD 132,174 compared to the previous valuation of Tandem Diabetes Care Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 34.34 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 34.34. The average price that TWST shares were previous bought at was USD 36.0684. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in TWST has increased by USD 132,358 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 18.32 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 18.32. The average price that TXG shares were previous bought at was USD 13.4831. The current market price is 35.9% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 232,611 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 18.32 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 18.32. The average price that TXG shares were previous bought at was USD 13.4831. The current market price is 35.9% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 232,611 compared to the previous valuation of Terex Corporation however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 274.939 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 274.939. The average price that UCB.BR shares were previous bought at was EUR 215.651. The current market price is 27.5% higher than average price they were purchased at. The value of the holding in UCB.BR has fallen by EUR 22,334 (USD $26,141) compared to the previous valuation of UCB SA |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 43.63 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 43.63. The average price that VCYT shares were previous bought at was USD 34.8676. The current market price is 25.1% higher than average price they were purchased at. The value of the holding in VCYT has increased by USD 109,765 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2026-01-05 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.79 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.79. The average price that VIR shares were previous bought at was USD 7.17028. The current market price is -19.3% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 18,326 compared to the previous valuation of Vir Biotechnology Inc |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.79 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.79. The average price that VIR shares were previous bought at was USD 7.17028. The current market price is -19.3% lower than average price they were purchased at. The value of the holding in VIR has fallen by USD 18,326 compared to the previous valuation of Vidrala S.A |
| VLA.PA - Valneva SE | HOLD | 0 @ EUR 4.41025 | EUR 0 | The current share valuation price of VLA.PA based on adjusted close was EUR 4.41025. The average price that VLA.PA shares were previous bought at was EUR 2.93259. The current market price is 50.4% higher than average price they were purchased at. The value of the holding in VLA.PA has fallen by EUR 7,554 (USD $8,842) compared to the previous valuation of Valneva SE |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 7.87001 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 7.87001. The average price that VNDA shares were previous bought at was USD 4.89461. The current market price is 60.8% higher than average price they were purchased at. The value of the holding in VNDA has fallen by USD 25,683 compared to the previous valuation of Vanda Pharmaceuticals Inc |
| VRDN - Viridian Therapeutics Inc | HOLD | 0 @ USD 30.2 | USD 0 | The current share valuation price of VRDN based on adjusted close was USD 30.2. The average price that VRDN shares were previous bought at was USD 30.2047. The current market price is 0.0% lower than average price they were purchased at. The value of the holding in VRDN has fallen by USD 48,142 compared to the previous valuation of Viridian Therapeutics Inc |
| XVIVO.ST - | HOLD | 0 @ SEK 18.9957 | SEK 0 | The current share valuation price of XVIVO.ST based on adjusted close was SEK 18.9957. The average price that XVIVO.ST shares were previous bought at was SEK 39.4797. The current market price is -51.9% lower than average price they were purchased at. The value of the holding in XVIVO.ST has fallen by SEK 20,577 (USD $2,230) compared to the previous valuation of |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 25.48 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 25.48. The average price that ZYME shares were previous bought at was USD 18.5094. The current market price is 37.7% higher than average price they were purchased at. The value of the holding in ZYME has fallen by USD 70,025 compared to the previous valuation of Zymeworks Inc. Common Stock |